BSECompany Update2d ago · 16 Nov 2026, 01:04 pm

Pls. find enclosed herewith Investor Presentation.

Dishman Carbogen Amcis Ltd · 540701

✦ AI SummaryResults

Dishman Carbogen Amcis Ltd has released its un-audited financial results for the second quarter and half year ended September 30, 2026, showing a decline in revenue and net profit compared to the same period last year.

Analysis Scores

Earnings Impact4/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Investor Presentation

Attachments (1)

📄

e7dadc06-3a5e-4b20-923e-d4fc4d2b560d.pdf

pdf

Download →
View document text
16th November, 2026 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, “Exchange Plaza”, C-1, Block G, Mumbai – 400 001. Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467, 977859, 978062, (ii) Series – EQ 978230 and 978323 (Debt) SUB: INVESTORS PRESENTATION ON UN-AUDITED FINANCIAL RESULT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026 – REGULATIONS: 30 and 51 Dear Sir, Pursuant to Regulations 30 and 51 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith Presentation on Un- Audited financial result for the second quarter and half year ended 30th September, 2026 to be made to Analyst and Investors. The aforesaid presentation is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulations 46 and 62 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Kindly take the same on your record. Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary Encl.: As above Investor Presentation Q2FY27 & H1FY27 Quater ended September 30, 2026 This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of Dishman about the business, industry and markets in which Dishman operates. SAFE HARBOR These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond Dishman’s STATEMENT control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of Dishman. In particular, such statements should not be regarded as a projection of future performance of Dishman. It should be noted that the actual performance or achievements of Dishman may vary significantly from such statements. 23 32 4 Solving Complex Problems for 250+ Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT Successful IN-ORGANIC Clients FACILITIES Globally and HIPO LABS GROWTH TRANSACTIONS DISHMAN IN Global Health Authorities CHF 98 M 2,100+ Team Strength decades Committed Members Embracing Approved & Recognized by our Culture of Innovation & A NUTSHELL of Long-Standing Track Record in NEW PRODUCT Sustainability DEVELOPMENT PIPELINE CDMO USFDA, MEB, SWISS MEDIC, Dedicated Team/Scientist Working SPECIALTIES, QUATS & ANSM, WHO, MFDS, PMDA, in R&D - 950+ GENERICS NMPA, EDQM 50% of Technical Staff holding Ph.D Commencement 13 30 Successful First Operations in of tech transfer of FDA Pre-Approval second molecule India, Switzerland, UK, Inspection at Its France, China and the Late Phase Total from Switzerland Commercialized Vionnaz Site Netherlands III molecules Molecules to India Revenue from Operations (₹ mn) EBITDA (₹ mn) and EBITDA % EBITDA EBITDA % 19.3% 17.3% 15.5% 14.3% 13.8% 11.0% HISTORICAL 0 7 9 8 5 9 2 0 2 5 1 1 3 4 2 5 0 6 1 4 1 1 1 3 4 1 2 6 9 5 , , , , , , 7 3 3 8 6 6 9 1 4 6 7 9 1 2 2 2 2 2 ,2 ,3 ,3 ,2 ,4 ,5 FINANCIAL FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 Strong basket of 14 molecules in Late Phase III development. PERFORMANCE CDMO (₹ mn) Marketable Molecules (₹ mn) 4 3 3 0 0 3 2 9 5 8 3 1 6 4 6 9 5 6 3 4 4 6 9 4 9 1 7 7 8 0 , 4 , 6 , 9 , 1 , 2 , 4 7 9 6 4 1 9 1 1 1 2 2 2 ,4 ,4 ,4 ,4 ,4 ,4 FY21 FY22 FY23 FY24 FY25 FY26 FY21 FY22 FY23 FY24 FY25 FY26 AGENDA 01 02 03 Quarter & Half Company Industry Year Highlights Overview Overview 02 03 Quarter & Company Industry Half Year Overview Overview Highlights NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%) 22.8% 26.0% 21.0% 16.0% 9.1% 11.0% 6,527 5,074 1,489 460 6.0% 1.0% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY27 RESULT HIGHLIGHTS SEGMENT WISE REVENUE BREAKUP (₹ mn) 1,433 1,186 5,094 3,887 Q2FY26 Q2FY27 CDMO Marketable Molecules NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN (%) 21.3% 26.0% 21.0% 16.0% 8.9% 11.0% 13,607 11,850 2,896 1,060 6.0% 1.0% H1FY26 H1FY27 H1FY26 H1FY27 H1FY27 RESULT HIGHLIGHTS SEGMENT WISE REVENUE BREAKUP (₹ mn) 2,401 2,560 11,206 9,290 H1FY26 H1FY27 CDMO Marketable Molecules Particulars (₹ mn) Q2FY27 Q2FY26 YoY % H1FY27 H1FY26 YoY % Income from Operations (Net) 5,073.7 6,526.5 -22.3% 11,850.1 13,607.0 -12.9% COGS 347.8 343.1 1.4% 1,490.1 1,324.0 12.5% Employee Expenses 3,216.2 3,329.4 -3.4% 7,107.2 6,848.4 3.8% Other Expenses 1,050.1 1,365.1 -23.1% 2,192.4 2,538.9 -13.6% EBITDA 459.6 1,488.9 -69.1% 1,060.4 2,895.7 -63.4% EBIDTA Margin % 9.1% 22.8% 8.9% 21.3% CONSOLIDATED Other Income 35.6 81.1 -56.1% 217.2 328.6 -33.9% Depreciation & Amortization 904.2 841.3 7.5% 1,811.0 1,654.8 9.4% P&L STATEMENT Finance Cost (Incl. Forex Impact) 401.0 423.3 -5.3% 771.9 850.9 -9.3% Exceptional Items (16.9) (26.5) Profit Before Tax (810.0) 305.4 -365.2% (1,322.2) 692.1 -291.0% Tax Expense (142.7) (347.3) (76.1) (194.7) Profit After Tax (667.3) 652.7 -202.2% (1,246.1) 886.8 -240.5% PAT Margin % -13.2% 10.0% -10.5% 6.5% Particulars (₹ mn) Sep-26 Mar-26 Particulars (₹ mn) Sep-26 Mar-26 Property, plant and equipment 28,098.9 29,419.3 Equity Share Capital 313.6 313.6 Capital Work in Progress 2,919.3 2,750.0 Other Equity 66,397.1 66,455.4 Right to use Lease Assets 1,870.7 2,262.9 Total - Shareholder Funds 66,710.7 66,769.0 Investment property 43.4 45.6 Goodwill 46,807.9 47,984.1 Long Term Borrowings 15,317.5 15,348.6 Other Intangible Assets 876.5 1,043.7 Lease Liabilities 1,798.0 2,232.9 Intangible Assets under development 3,237.0 2,953.1 Other Financial Liabilities 229.8 288.1 Investments 752.8 752.8 Provisions 2,287.3 4,279.3 Long Term Loans and Advances 19.2 19.0 Other Financial Assets 183.1 194.0 Deferred Tax Liabilities (Net) 248.2 119.1 Deferred tax assets (net) 777.2 833.6 Other Non-Current liabilities 4,158.9 7,025.6 CONSOLIDATED Current Tax Assets 966.6 1,300.4 Total - Non-Current Liabilities 24,039.7 29,293.6 Other Non-Current Assets 1,270.3 1,253.6 Short Term Borrowings 16,319.4 12,405.4 Balance Sheet Total - Non-Current Assets 87,822.9 90,812.1 Inventories 11,127.6 10,191.2 Lease Liabilities 736.6 773.7 Investments 166.2 161.7 Trade Payables 2,754.3 2,111.8 Trade Receivables 4,703.9 6,729.1 Other Financial Liabilities 2,223.3 3,490.2 Cash and cash equivalents 10,090.9 7,877.6 Other Current Liabilities 4,565.0 3,358.2 Bank balances 1,961.8 2,034.5 Short Term Loans and Advances 33.4 32.5 Short Term Provisions 19.5 143.3 Other Financial Assets 493.3 234.2 Current Tax Liabilities (Net) 592.5 887.9 Other Current Assets 1,561.0 1,160.2 Total - Current Liabilities 27,210.6 23,170.5 Total - Current Assets 30,138.1 28,421.0 Total - Equities & Liabilities 1,17,961.0 1,19,233.1 Total - Assets 1,17,961.0 1,19,233.1 As per Reported figures Revenue (₹ mn) Q2FY27 Q2FY26 H1FY27 H1FY26 CDMO 3,887.5 5,094.0 9,290.4 11,206.4 Marketable Molecules 1,186.2 1,432.5 2,559.7 2,400.6 Total Revenue 5,073.7 6,526.5 11,850.1 13,607.0 REVENUE Total Operating Revenue – Q2FY27 Total Operating Revenue – H1FY27 BREAKUP 23% 22% ANALYSIS & CDMO H1FY27 Q2FY27 MARGIN Marketable Molecules BREAKUP 77% 78% ANALYSIS EBITDA Margin % Q2FY27 Q2FY26 H1FY27 H1FY26 CDMO 12.3% 25.3% 8.7% 21.3% Marketable Molecules -1.6% 14.0% 9.7% 21.4% ➢ Net Revenue at ₹ 11,805 mn in H1FY27 down by 12.9% YoY, primarily due to lower revenue from CDMO segment. ➢ CDMO revenue declined by 17.1% YoY in H1FY27, mainly due to lowe [Showing first 8,000 characters — download PDF for full document]